71
Participants
Start Date
February 28, 2010
Primary Completion Date
September 30, 2014
Study Completion Date
September 30, 2014
Panitumumab
6 mg/kg IV on Day 1 of each 2-week treatment cycle for 3 cycles (6 weeks)
Carboplatin
AUC=2.5 IV, Day 1 of each 2-week treatment cycle for 3 cycles (6 weeks)
Gemcitabine
1500 mg/m2 IV, Day 1 of each 2-week treatment cycle for 3 cycles (6 weeks)
Center for Cancer and Blood Disorders, Bethesda
National Capital Clinical Research Consortium, Bethesda
Peninsula Cancer Institute, Newport News
Aventura Hospital and Medical Center, Aventura
Tennessee Oncology, Nashville
Chattanooga Oncology Hematology Associates, Chattanooga
Family Cancer Center, Collierville
Norton Cancer Institute, Louisville
Oncology Hematology Care, Cincinnati
Providence Medical Group, Terre Haute
St. Louis Cancer Care, Chesterfield
Research Medical Center, Kansas City
Nebraska Methodist Cancer Center, Omaha
Texas Health Physician Group, Dallas
Los Robles, Thousand Oaks
Florida Cancer Specialists, Fort Myers
Atlantic Health System, Morristown
Collaborators (1)
Amgen
INDUSTRY
Eli Lilly and Company
INDUSTRY
SCRI Development Innovations, LLC
OTHER